Women’s health company bolsters fat IP portfolio with new SAM-e formula

By Hank Schultz contact

- Last updated on GMT

©Getty Images - Allison Michael Orenstein
©Getty Images - Allison Michael Orenstein

Related tags: SAM-e

Bonafide, a company focused on healthcare products for women, has acquired the rights to an enhanced S-adenosylmethionine (SAM-e) formulation. The company said the acquisition means it now has more than 50 issued or pending patents that it owns or has licensed.

SAM-e is a naturally occurring endogenous compound that has been studied for a number of health effects.  While synthesized forms of the molecule have been sold as supplements in the United States it has been offered as a prescription drug in some part of Europe.

The compound has been most studied for ameliorating the pain and inflammation associated with osteoarthritis.  It has also been studied in connection with depression and other neuropsychiatric conditions.  And it has purported liver health support attributes.

Higher bioavailability

The form Bonafide has acquired is dubbed MSI-195 and was developed by MSI Methylation Sciences, Inc., a small Canadian pharmaceutical firm. MSI had research showing the formulation was 2.8 times more bioavailable than a comparison commercial SAM-e formulation​ as measured on an area-under-the-curve basis.

“This unique and potent form of SAM-e has been studied as a potential pharmaceutical product over the past decade with a significant amount of safety, pre-clinical and clinical research supporting the enhanced bioavailability of this compound. We are very enthusiastic about MSI-195 because it has the potential to help women in a number of important areas, including mood,” ​said Jim Komorowski, Bonafide's chief science officer.

Menopause market

Last year Bonafide conducted consumer research on menopause​, which aggregated the symptoms, treatments, and general dispositions of over 1,000 US women ages 40 to 65 in the US. 

More than 70% of women reported that they were not currently treating their menopause, which included hot flashes (16%), weight gain (15%), difficulties with sleep (14%), and night sweats (14%), and brain fog (10%). 

While most of these symptoms negatively impact the day-to-day life of menopausal women, 73% of women report they are not currently treating their symptoms and 20% of women experienced such symptoms for 12+ months before even being assessed by an HCP,”​ said OB/GYN Alyssa Dweck, MS, MD, Chief Medical Officer at Bonafide.

"During my over 25 years in practice as an OB-GYN, I have seen that women want and need non-drug, natural alternatives for the treatment of symptoms from hormonal changes during menopause,”​ Dr Dweck added.

Bonafide, which launched in 2018, says it now has more than 120,000 customers and a 92% retention rate.  The company has five signature natural menopause symptom relief solutions, in addition to a line of everyday vitamins.

Related news

Show more

Related products

show more

The Year of

The Year of "Destination Health" Has Arrived

Blue California | 01-Apr-2022 | Infographic

Consumers are pursuing prevention over cure as the ticket to long-term health and wellness. While immunity is at the forefront of health, consumers are...

Confidence on Evidence: Theracurmin® on Joint Pain

Confidence on Evidence: Theracurmin® on Joint Pain

Theravalues Corporation | 28-Mar-2022 | Clinical Study

The Arthritis Foundation* (arthritis.org) mentions curcumin as a supplement that eases symptoms of arthritis. However, curcumin represents only a small...

Related suppliers

Follow us

Products

View more

Webinars